[go: up one dir, main page]

WO2009034541A9 - Controlled release pharmaceutical dosage forms of trimetazidine - Google Patents

Controlled release pharmaceutical dosage forms of trimetazidine Download PDF

Info

Publication number
WO2009034541A9
WO2009034541A9 PCT/IB2008/053679 IB2008053679W WO2009034541A9 WO 2009034541 A9 WO2009034541 A9 WO 2009034541A9 IB 2008053679 W IB2008053679 W IB 2008053679W WO 2009034541 A9 WO2009034541 A9 WO 2009034541A9
Authority
WO
WIPO (PCT)
Prior art keywords
trimetazidine
dosage form
pharmaceutically acceptable
controlled release
release
Prior art date
Application number
PCT/IB2008/053679
Other languages
French (fr)
Other versions
WO2009034541A3 (en
WO2009034541A2 (en
Inventor
Sweta Varshney
Anant Ramesh Katkar
Kalaiselvan Ramaraju
Rajan Kumar Verma
Rajeev Singh Raghuvanshi
Himadri Sen
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP08807614A priority Critical patent/EP2200591A2/en
Publication of WO2009034541A2 publication Critical patent/WO2009034541A2/en
Publication of WO2009034541A3 publication Critical patent/WO2009034541A3/en
Publication of WO2009034541A9 publication Critical patent/WO2009034541A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing.
  • Trimetazidine [l-(2,3,4-trimethoxybenzyl piperazine] is a 3-ketoacyl-coenzyme A thiolase inhibitor with a cytoprotective effect, which by preserving the energy metabolisms of the cell exposed to the hypoxia or ischaemia, avoids the collapse of the intracellular rate of adenosine triphosphate (ATP). Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
  • ATP adenosine triphosphate
  • Trimetazidine dihydrochloride is used therapeutically in the long-term treatment of angina pectoris. It is freely soluble in water and has two pKa values 4.32 and 8.95. Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels. Servier had developed a modified-release dosage form containing 35mg for twice- daily administration, marketed under the brand name "VASTAREL MR".
  • This dosage form was bioequivalent to the 20 mg conventional thrice-a-day formulation of trimetazidine hydrochloride.
  • the modified-release formulation is based on a hydrophilic matrix that utilizes polymers which swell in contact with gastrointestinal fluids to form gels.
  • This formulation has been covered by Servier in a European patent published as EP 1 108 424, which discloses a matrix tablet enabling prolonged release of trimetazidine comprised of cellulose derivative polymers.
  • the formulation described releases more than 90% of the drug in-vitro within a period of 4 hours.
  • European patent EP 0 673 649 also assigned to Servier describes pharmaceutical compositions for the prolonged release of trimetazidine wherein prolonged release is ensured by the reservoir system.
  • the composition is prepared by compression of the active ingredient mixture and excipient, which are then coated with an insoluble polymer.
  • hydrophilic polymers for controlling the release of trimetazidine from the controlled release pharmaceutical compositions.
  • water-soluble salts such as hydrochloride salt of trimetazidine, it may result in burst release or dose dumping.
  • the PCT application WO 03/043610 filed by Themis Laboratories discloses a process for manufacturing microbeads, which enable "once a day” dosing for 60 mg dose of trimetazidine dihydrochloride per unit dose.
  • the application further provides dissolution rates at different time periods which correspond to 24 hours therapeutic blood levels. Further, it discloses the dissolution rate to be not less than 65% w/w in 6 hours.
  • the European patent application EP 1 195 160 filed by USV discloses a sustained release dosage form of trimetazidine that releases more than 90% of the drug in- vitro within a period of about 6 hours to about 8 hours.
  • the dosage form employs hydrophobic substance and a hydrocolloid for sustaining the release.
  • a controlled in vitro release of trimetazidine is of most importance in the context of in vivo drug profiles.
  • Drug absorption from a solid dosage form following oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance.
  • trimetazidine taking into account the great therapeutic interest of trimetazidine, there exists a need in the state of the art for new pharmaceutical dosage forms for "once a day” dosing of trimetazidine, prepared by a simpler process that is cost-effective and yields a dosage form with pH independent release of trimetazidine for at least 16 hours without any lag period.
  • the present invention provides new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping.
  • the pharmaceutical dosage form of the present invention uses a cost effective and rapid operation process.
  • water-insoluble polymers have been employed as a coating polymer in reservoir systems, these systems produced a release profile where trimetazidine hydrochloride is not available for immediate absorption and pharmacological action.
  • Other factors such as complexity of process, need for specialized equipment, incomplete release, etc. may also limit its use.
  • the present invention utilizes a simpler process of employing water-insoluble polymers as the matrix forming polymer.
  • the water insoluble polymers due to their nature, may result in a slower release, particularly in the beginning, leading to a lag phase. This is mainly due to less intake of aqueous medium.
  • a water swellable polymer may be incorporated in the matrix which results in increased early wetting.
  • a controlled release monolithic matrix dosage form comprising:
  • trimetazidine or its pharmaceutically acceptable salts
  • one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and
  • the dosage forms contain about 50 mg to about 80 mg of trimetazidine.
  • controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70 mg of trimetazidine.
  • Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine based upon the total weight of the dosage form.
  • water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof.
  • the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two.
  • the water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form.
  • the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
  • water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. Particularly the water swellable rate controlling polymer is xanthan gum.
  • the water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
  • the highly water soluble drug trimetazidine or one of its salts is dispersed in a hydrophobic material.
  • a controlled release monolithic matrix dosage form of trimetazidine comprising:
  • rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • hydrophobic material examples include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C ⁇ -Ci 8 fatty acids or mineral oil or mixtures thereof.
  • the hydrophobic material comprises carnauba wax, stearic acid or mixtures thereof.
  • the hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
  • step (b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • step (b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
  • a part of the rate controlling polymer is added along with the active.
  • the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
  • a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of: (a) dispersing trimetazidine in at least one hydrophobic material;
  • step (b) milling the material of step (a);
  • step (c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients;
  • step (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • step (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a);
  • step (c) granulating the material of step (b) with a rate controlling polymer and other excipients;
  • step (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the active is dispersed in at least one hydrophobic material with the help of solvents or by melting the hydrophobic material slightly above its melting point and dispersing the active in it.
  • the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
  • a part of the rate controlling polymer is added along with the active.
  • the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
  • Example of solvents used for granulation comprise methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water or mixtures thereof.
  • the hydrophobic materials were melted at temperatures ranging from about 4O 0 C to about 120° C. Particularly, the hydrophobic materials were melted at a temperature range of about 60° C to about 80° C.
  • the controlled release dosage forms comprise one or more pharmaceutically acceptable excipients selected from one or more of binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
  • the dosage form is optionally coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
  • a method of prophylactic treatment of angina pectoris comprising administering a controlled release monolithic matrix dosage form of trimetazidine, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.
  • the details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and claims.
  • the present invention relates to controlled release dosage forms of trimetazidine suitable for once-daily dosing, containing less than about lOOmg of trimetazidine.
  • the dosage forms Preferably contain about 50 mg to about 80 mg of trimetazidine.
  • controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70mg of trimetazidine.
  • Trimetazidine used herein should be understood as the base or any of its pharmaceutically acceptable salt thereof. Particularly, the salt is dihydrochloride. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine.
  • controlled-release includes any type of controlled- release including prolonged release, sustained release, modified release and extended release.
  • the pharmaceutical dosage forms of the present invention can be administered orally in the form of tablets or capsules filled with pellets, beads, granules, multiparticulates, tablets or powder.
  • the present invention employs water insoluble polymeric matrix to control the release of highly water soluble trimetazidine.
  • a water swellable polymer is also added to the matrix to allow the aqueous medium to penetrate the dosage form and provide a tortuous path for uniform drug release.
  • the active is released uniformly over a period of 12 to 24 hours in a substantially linear or zero order release.
  • water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof.
  • the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two.
  • the water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form.
  • the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
  • water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide.
  • the water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
  • trimetazidine from the dosage form is further controlled in the early phase and a near zero-order release profile is obtained when the drug is dispersed in a hydrophobic material.
  • hydrophobic material examples include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C ⁇ -Ci 8 fatty acids or mineral oil or mixtures thereof.
  • the hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
  • the controlled release dosage forms may further comprise one or more pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients are those known to the skilled in the art and may be selected from binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
  • binders include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, agar, tragacanth, sodium alginate and propylene glycol.
  • fillers or diluents include, but are not limited to, corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium dihydrogen phosphate dihydrates, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch and starch pregelatinized.
  • the fillers comprise microcrystalline cellulose, calcium dihydrogen phosphate dihydrate or a mixture of both.
  • lubricants and glidants include, but are not limited to, colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax and white beeswax.
  • the coloring agents and flavoring agents of the present invention may be selected from any FDA approved colors and flavors for oral use.
  • the ingredients discussed above may be formed into dosage forms by conventional techniques, for example either by direct compression, or first compacting some of the ingredients, milling the compacts, blending with the remaining ingredients and then compressing as appropriate.
  • the controlled release monolithic matrix dosage forms may also be prepared using wet granulation techniques.
  • the process may include granulation of trimetazidine and the rate controlling polymers with a solvent or granulation of trimetazidine with a solution of the polymer.
  • the process may further include drying the granules prior to compressing into tablets.
  • controlled release dosage forms of the present invention can optionally be coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
  • Coating may be performed by applying one or more film forming polymers with or without other pharmaceutically inert excipients. This may be done as a solution or suspensions using any conventional coating technique known in the prior art, such as spray coating in a conventional coating pan or fluidized bed processor, or dip coating.
  • Suitable film forming polymers include one or more of ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, waxes, methacrylic acid polymers such as Eudragit® RL and RS, and mixtures thereof.
  • the coating can also be performed using any commercially available ready to coat preparations such as Opadry-AMB, Opadry- White, Opadry-Clear, etc.
  • Suitable solvents used for making a solution/suspension of film forming polymer include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
  • a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
  • the controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.
  • Trimetazidine dihydrochloride, microcrystalline cellulose (High viscosity), xanthiin gum & ethylcellulose (High viscosity) were mixed and granulated with ethylcellulose (Low viscosity).
  • step-1 Granules of step-1 were blended with microcrystalline cellulose (Low viscosity), carbopoL colloidal silicon dioxide and magnesium stearate.
  • the controlled release (CR) dosage forms prepared according to Examples 1, 2 and 3 were subjected to in vitro drug release test which utilizes the United States Pharmacopeia (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
  • USP United States Pharmacopeia
  • Table 1 Drug Release of Trimetazidine CR dosage forms prepared as per Examples 1, 2 and 3 in Phosphate buffer pH 6.8, SOO ml, USP 1 at 100 rpm.
  • Trimelazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
  • step 1 Dispersion of step 1 was stirred till it cooled.
  • step 2 Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; colloidal silicon dioxide and magnesium stearate.
  • Example 5 Controlled release monolithic matrix dosage form of trimetazidine dihvdrochloride
  • Trimelazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
  • step 1 Dispersion of step 1 was stirred till it cooled. 1.
  • Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; calcium dihydrogen phosphate dihydrate; colloidal silicon dioxide and magnesium stearate.
  • step 3 Material of step 3 was compressed into tablets.
  • step 4 Tablets of step 4 were coated with the coating composition.
  • the controlled release (CR) dosage form prepared according to Example 5 were subjected to in vitro drug release test which utilizes the United States Pharmacopeia (IJSP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
  • IJSP United States Pharmacopeia
  • Table 2 In Vitro Release of Trimetazidine CR dosage form prepared as per Example 5 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.
  • Table 3 Pharmacokinetic data for controlled release (CR) monolithic matrix dosage forms prepared as per present invention. Once daily vs. three doses of VASTAREL 20 mg tablets (containing trimetazidine 20 mg) administered thrice daily
  • Table 4 Pharmacokinetic data for controlled release monolithic matrix dosage forms prepared as per present invention. Once daily vs. two doses of VASTAREL MR 35 mg tablets (containing trimetazidiue 35 mg) administered twice daily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to new solid dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping.

Description

CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF
TRIMETAZIDINE
Field of the Invention
The present invention relates to new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing.
Background of the Invention
Trimetazidine [l-(2,3,4-trimethoxybenzyl piperazine] is a 3-ketoacyl-coenzyme A thiolase inhibitor with a cytoprotective effect, which by preserving the energy metabolisms of the cell exposed to the hypoxia or ischaemia, avoids the collapse of the intracellular rate of adenosine triphosphate (ATP). Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
Trimetazidine dihydrochloride is used therapeutically in the long-term treatment of angina pectoris. It is freely soluble in water and has two pKa values 4.32 and 8.95. Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels. Servier had developed a modified-release dosage form containing 35mg for twice- daily administration, marketed under the brand name "VASTAREL MR". This dosage form was bioequivalent to the 20 mg conventional thrice-a-day formulation of trimetazidine hydrochloride. The modified-release formulation is based on a hydrophilic matrix that utilizes polymers which swell in contact with gastrointestinal fluids to form gels. This formulation has been covered by Servier in a European patent published as EP 1 108 424, which discloses a matrix tablet enabling prolonged release of trimetazidine comprised of cellulose derivative polymers. The formulation described releases more than 90% of the drug in-vitro within a period of 4 hours.
European patent EP 0 673 649 also assigned to Servier describes pharmaceutical compositions for the prolonged release of trimetazidine wherein prolonged release is ensured by the reservoir system. The composition is prepared by compression of the active ingredient mixture and excipient, which are then coated with an insoluble polymer.
The prior art describes the use of hydrophilic polymers for controlling the release of trimetazidine from the controlled release pharmaceutical compositions. However, for water-soluble salts such as hydrochloride salt of trimetazidine, it may result in burst release or dose dumping.
The PCT application WO 03/043610 filed by Themis Laboratories, discloses a process for manufacturing microbeads, which enable "once a day" dosing for 60 mg dose of trimetazidine dihydrochloride per unit dose. The application further provides dissolution rates at different time periods which correspond to 24 hours therapeutic blood levels. Further, it discloses the dissolution rate to be not less than 65% w/w in 6 hours.
The European patent application EP 1 195 160 filed by USV, discloses a sustained release dosage form of trimetazidine that releases more than 90% of the drug in- vitro within a period of about 6 hours to about 8 hours. The dosage form employs hydrophobic substance and a hydrocolloid for sustaining the release.
A controlled in vitro release of trimetazidine is of most importance in the context of in vivo drug profiles. Drug absorption from a solid dosage form following oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance.
Therefore, taking into account the great therapeutic interest of trimetazidine, there exists a need in the state of the art for new pharmaceutical dosage forms for "once a day" dosing of trimetazidine, prepared by a simpler process that is cost-effective and yields a dosage form with pH independent release of trimetazidine for at least 16 hours without any lag period.
The present invention provides new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping. The pharmaceutical dosage form of the present invention uses a cost effective and rapid operation process.
Although water-insoluble polymers have been employed as a coating polymer in reservoir systems, these systems produced a release profile where trimetazidine hydrochloride is not available for immediate absorption and pharmacological action. Other factors such as complexity of process, need for specialized equipment, incomplete release, etc. may also limit its use.
The present invention utilizes a simpler process of employing water-insoluble polymers as the matrix forming polymer. However, the water insoluble polymers, due to their nature, may result in a slower release, particularly in the beginning, leading to a lag phase. This is mainly due to less intake of aqueous medium. To avoid this, a water swellable polymer may be incorporated in the matrix which results in increased early wetting. Summary of the Invention
In one general aspect there is provided a controlled release monolithic matrix dosage form comprising:
(a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and
(c) one or more pharmaceutically acceptable excipients, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours. Controlled release dosage forms of trimetazidine suitable for once-daily dosing, contain less than about lOOmg of trimetazidine.
Particularly the dosage forms contain about 50 mg to about 80 mg of trimetazidine. Particularly, controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70 mg of trimetazidine. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine based upon the total weight of the dosage form.
Examples of water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof. Particularly the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two. The water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form. Particularly the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
Examples of water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. Particularly the water swellable rate controlling polymer is xanthan gum.
The water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
To further control the release in the early phase and to obtain a near zero-order release profile, the highly water soluble drug trimetazidine or one of its salts is dispersed in a hydrophobic material.
In another aspect there is provided a controlled release monolithic matrix dosage form of trimetazidine comprising:
(a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts,
(b) at least one hydrophobic material, and
(c) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
Examples of hydrophobic material include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of Cό-Ci8 fatty acids or mineral oil or mixtures thereof.
Particularly, the hydrophobic material comprises carnauba wax, stearic acid or mixtures thereof.
The hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:
(a) blending/mixing trimetazidine and one or more rate controlling polymers with one or more pharmaceutically acceptable excipients, and
(b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:
(a) granulating trimetazidine, atleast one pharmaceutically acceptable excipient and one or more rate controlling polymers,
(b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours. In one of the embodiments, the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
In another embodiment, a part of the rate controlling polymer is added along with the active. Alernatively, the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of: (a) dispersing trimetazidine in at least one hydrophobic material;
(b) milling the material of step (a);
(c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients;
(d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:
(a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a);
(c) granulating the material of step (b) with a rate controlling polymer and other excipients;
(d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
The active is dispersed in at least one hydrophobic material with the help of solvents or by melting the hydrophobic material slightly above its melting point and dispersing the active in it. In one of the embodiments, the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.
In another embodiment, a part of the rate controlling polymer is added along with the active. Alernatively, the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.
Example of solvents used for granulation comprise methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water or mixtures thereof. The hydrophobic materials were melted at temperatures ranging from about 4O0C to about 120° C. Particularly, the hydrophobic materials were melted at a temperature range of about 60° C to about 80° C.
The controlled release dosage forms comprise one or more pharmaceutically acceptable excipients selected from one or more of binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
In another embodiment, the dosage form is optionally coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
In another aspect there is provided a method of prophylactic treatment of angina pectoris comprising administering a controlled release monolithic matrix dosage form of trimetazidine, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
The controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and claims.
Detailed Description of the Invention
The present invention relates to controlled release dosage forms of trimetazidine suitable for once-daily dosing, containing less than about lOOmg of trimetazidine. Preferably the dosage forms contain about 50 mg to about 80 mg of trimetazidine. Particularly, controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70mg of trimetazidine.
Trimetazidine used herein should be understood as the base or any of its pharmaceutically acceptable salt thereof. Particularly, the salt is dihydrochloride. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine.
The term "controlled-release", as used herein, includes any type of controlled- release including prolonged release, sustained release, modified release and extended release.
The pharmaceutical dosage forms of the present invention can be administered orally in the form of tablets or capsules filled with pellets, beads, granules, multiparticulates, tablets or powder.
The present invention employs water insoluble polymeric matrix to control the release of highly water soluble trimetazidine. A water swellable polymer is also added to the matrix to allow the aqueous medium to penetrate the dosage form and provide a tortuous path for uniform drug release. The active is released uniformly over a period of 12 to 24 hours in a substantially linear or zero order release.
Examples of water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof. Particularly the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two. The water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form. Particularly the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.
Examples of water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. The water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.
The release of trimetazidine from the dosage form is further controlled in the early phase and a near zero-order release profile is obtained when the drug is dispersed in a hydrophobic material.
Examples of hydrophobic material include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of Cό-Ci8 fatty acids or mineral oil or mixtures thereof. The hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.
The controlled release dosage forms may further comprise one or more pharmaceutically acceptable excipients.
The pharmaceutically acceptable excipients are those known to the skilled in the art and may be selected from binders, fillers, lubricants, glidants, coloring agents and flavoring agents.
Examples of binders include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, agar, tragacanth, sodium alginate and propylene glycol. Examples of fillers or diluents include, but are not limited to, corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium dihydrogen phosphate dihydrates, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch and starch pregelatinized.
Particularly, the fillers comprise microcrystalline cellulose, calcium dihydrogen phosphate dihydrate or a mixture of both.
Examples of lubricants and glidants include, but are not limited to, colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax and white beeswax.
The coloring agents and flavoring agents of the present invention may be selected from any FDA approved colors and flavors for oral use. The ingredients discussed above may be formed into dosage forms by conventional techniques, for example either by direct compression, or first compacting some of the ingredients, milling the compacts, blending with the remaining ingredients and then compressing as appropriate.
The controlled release monolithic matrix dosage forms may also be prepared using wet granulation techniques. The process may include granulation of trimetazidine and the rate controlling polymers with a solvent or granulation of trimetazidine with a solution of the polymer. The process may further include drying the granules prior to compressing into tablets.
The controlled release dosage forms of the present invention can optionally be coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
Coating may be performed by applying one or more film forming polymers with or without other pharmaceutically inert excipients. This may be done as a solution or suspensions using any conventional coating technique known in the prior art, such as spray coating in a conventional coating pan or fluidized bed processor, or dip coating.
Suitable film forming polymers include one or more of ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, waxes, methacrylic acid polymers such as Eudragit® RL and RS, and mixtures thereof. The coating can also be performed using any commercially available ready to coat preparations such as Opadry-AMB, Opadry- White, Opadry-Clear, etc. Suitable solvents used for making a solution/suspension of film forming polymer include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
Use of a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris is provided, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
The controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.
EXAMPLES
Examples 1. 2 & 3: Controlled release monolithic matrix dosage forms of trimetazidine dihvdrochloride
Figure imgf000012_0001
Process:
1. Trimetazidine dihydrochloride, microcrystalline cellulose (High viscosity), xanthiin gum & ethylcellulose (High viscosity) were mixed and granulated with ethylcellulose (Low viscosity).
2. Granules of step-1 were blended with microcrystalline cellulose (Low viscosity), carbopoL colloidal silicon dioxide and magnesium stearate.
3. Blend of step-2 was compressed into tablets.
The controlled release (CR) dosage forms prepared according to Examples 1, 2 and 3 were subjected to in vitro drug release test which utilizes the United States Pharmacopeia (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C. The results of the in vitro release test are given in Table 1.
Table 1: Drug Release of Trimetazidine CR dosage forms prepared as per Examples 1, 2 and 3 in Phosphate buffer pH 6.8, SOO ml, USP 1 at 100 rpm.
Figure imgf000013_0001
Fvample 4- Controlled release monolithic matrix dosage form of trimetazidine dihvdrochloride
Figure imgf000014_0001
Process:
1. Trimelazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
2. Dispersion of step 1 was stirred till it cooled.
3. Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; colloidal silicon dioxide and magnesium stearate.
4. Blend of step 3 was compressed into tablets.
Example 5: Controlled release monolithic matrix dosage form of trimetazidine dihvdrochloride
Figure imgf000015_0001
Process:
1. Trimelazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.
2. Dispersion of step 1 was stirred till it cooled. 1. Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; calcium dihydrogen phosphate dihydrate; colloidal silicon dioxide and magnesium stearate.
2. Material of step 3 was compressed into tablets.
3. Tablets of step 4 were coated with the coating composition.
The controlled release (CR) dosage form prepared according to Example 5 were subjected to in vitro drug release test which utilizes the United States Pharmacopeia (IJSP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C. The results of the in vitro drug release test are given in Table 2
Table 2: In Vitro Release of Trimetazidine CR dosage form prepared as per Example 5 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.
Figure imgf000016_0001
In vivo Bioequivalence Study
In vivo performance of a single dose of trimetazidine controlled release dosage forms as per present invention administered once daily (OD) were evaluated with respect to three doses of VASTAREL 20 mg tablets (Immediate release pτoduct of trimetazidine) administered thrice daily and two doses of VASTAREL MR 35 mg tablets (Modified release product of trimetazidine) administered twice daily under fasting and fed conditions in healthy male volunteers. Pharmacokinetic parameters Cmax (Peak serum concentration); AUCt (Area under the plasma concentration vs. time curve); and AUCinf (Area under the plasma concentration vs. time curve upto infinity) were calculated from the data obtained. The results of the study are given in Tables 3 and 4.
Table 3: Pharmacokinetic data for controlled release (CR) monolithic matrix dosage forms prepared as per present invention. Once daily vs. three doses of VASTAREL 20 mg tablets (containing trimetazidine 20 mg) administered thrice daily
Figure imgf000017_0001
Table 4: Pharmacokinetic data for controlled release monolithic matrix dosage forms prepared as per present invention. Once daily vs. two doses of VASTAREL MR 35 mg tablets (containing trimetazidiue 35 mg) administered twice daily
Figure imgf000018_0001
While there has been shown and described what are the preferred embodiments of the invention, one; skilled in the pharmaceutical formulation art will appreciate that various modifications in the dosage forms and process can be made without departing from the scope of the invention as it is defined by the appended claims.

Claims

CLAIMS: 1. A controlled release monolithic matrix dosage form comprising: (a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and (c) one or more pharmaceutically acceptable excipients, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
2. The dosage form of claim 1, further comprising trimetazidine or its pharmaceutically acceptable salt dispersed in at least one hydrophobic material.
3. A controlled release monolithic matrix dosage form of trimetazidine comprising: (a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) atleast one hydrophobic material, and (c) one or more rate controlling polymers selected from the group consisting of a water-insoluble polymer , water-swellable polymer and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
4. The dosage form according to claims 1-3, wherein the in vitro release is measured by a drug release test which utilizes the United States Pharmacopoeia (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
5. The dosage form according to claims 1-3, wherein the water-insoluble polymer comprises ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof and wherein the water-insoluble polymer comprises about 20 to about 60% by weight of the dosage form.
6. The dosage form according to claims 1-3, wherein the water swellable polymer comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide or mixtures thereof.
7. The dosage form according to claim 6, wherein the water swellable polymer is xanthan gum.
8. The dosage form according to claim 6, wherein the water swellable polymer comprises about 7% to about 60% by weight of the dosage form.
9. The dosage form according to claim 3, wherein the hydrophobic material comprises fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C6- Ci8 fatty acids, mineral oil, or mixtures thereof.
10. The dosage form according to claim 9, wherein the hydrophobic material comprises carnauba wax, stearic acid, or mixtures thereof.
11. The dosage form according to claim 9, wherein the hydrophobic material comprises about 20 to about 60% by weight of the dosage form.
12. The dosage form according to claims 1-3, further comprising pharmaceutically acceptable excipients selected from one or more of fillers, binders, lubricants, glidants, coloring agents and flavoring agents.
13. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 1 comprising the steps of: (a) blending/mixing trimetazidine and one or more rate controlling polymers with one or more pharmaceutically acceptable excipients, and (b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
14. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 1 comprising the steps of: (a) granulating trimetazidine, atleast one pharmaceutically acceptable excipient and one or more rate controlling polymers, (b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
15. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 3 comprising the steps of: (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a); (c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients; (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
16. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 3 comprising the steps of: (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a); (c) granulating the material of step (b) with a rate controlling polymer and other excipients; (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
17. A process of preparing a controlled release monolithic matrix dosage form of trimetazidine according to claims 15 and 16, wherein trimetazidine is dispersed in a molten mass of the hydrophobic material.
18. The dosage form according to the preceding claims, wherein the dosage form is further coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
19. Use of a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
PCT/IB2008/053679 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine WO2009034541A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08807614A EP2200591A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1925DE2007 2007-09-11
IN1925/DEL/2007 2007-09-11
IN1226/DEL/2008 2008-05-16
IN1226DE2008 2008-05-16

Publications (3)

Publication Number Publication Date
WO2009034541A2 WO2009034541A2 (en) 2009-03-19
WO2009034541A3 WO2009034541A3 (en) 2009-07-30
WO2009034541A9 true WO2009034541A9 (en) 2009-12-30

Family

ID=40120263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/053679 WO2009034541A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Country Status (2)

Country Link
EP (1) EP2200591A2 (en)
WO (1) WO2009034541A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CN109908096A (en) * 2017-12-12 2019-06-21 武汉武药科技有限公司 A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN110623934A (en) * 2019-09-26 2019-12-31 杭州百诚医药科技股份有限公司 Trimetazidine hydrochloride sustained release tablet and preparation method thereof
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201001902A2 (en) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Trimetazidine tablets with extended release
US20110274751A1 (en) * 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
CN102824644B (en) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 High-stability sustained-release tablet prepared by using hydroxy propyl cellulose
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
EP3525771A4 (en) 2016-11-21 2020-05-27 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
US20180190374A1 (en) * 2017-01-03 2018-07-05 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury
CN111888476A (en) * 2020-08-17 2020-11-06 深圳市道科思医药有限公司 Modified release pharmaceutical composition of trimetazidine dihydrochloride

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistent tablets
FR2717687B1 (en) 1994-03-24 1996-06-14 Adir Pharmaceutical compositions for the sustained release of trimetazidine after oral administration.
FR2802424B1 (en) 1999-12-17 2002-02-15 Adir MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION
DE60042972D1 (en) * 2000-10-05 2009-10-29 Usv Ltd Delayed-release drug-containing trimetazidine and method of preparation
FR2818549B1 (en) * 2000-12-26 2003-02-07 Servier Lab SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF TRIMETAZIDINE
AU2002356425A1 (en) 2001-11-21 2003-06-10 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe
FR2885807B1 (en) * 2005-05-18 2008-05-16 Mg Pharma SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10675278B2 (en) 2005-02-04 2020-06-09 Grünenthal GmbH Crush resistant delayed-release dosage forms
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CN109908096A (en) * 2017-12-12 2019-06-21 武汉武药科技有限公司 A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof
CN110623934A (en) * 2019-09-26 2019-12-31 杭州百诚医药科技股份有限公司 Trimetazidine hydrochloride sustained release tablet and preparation method thereof

Also Published As

Publication number Publication date
WO2009034541A3 (en) 2009-07-30
WO2009034541A2 (en) 2009-03-19
EP2200591A2 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
WO2009034541A9 (en) Controlled release pharmaceutical dosage forms of trimetazidine
US20210386691A1 (en) Oral Dosage Forms of Ketamine
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
JP6058000B2 (en) Sustained release formulation of ivabradine or a pharmaceutically acceptable salt thereof
JPH11505542A (en) Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing
EP2448561B1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
JPH061716A (en) Dosage form with long-term release of active ingredient
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
US20230012071A1 (en) Modified release pharmaceutical compositions of riociguat
WO2022144919A1 (en) Extended release pharmaceutical compositions of riociguat
WO2012020301A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
KR20180097623A (en) Appreciation Last formulation
FI100303B (en) Process for the preparation of an orally ingested buspirone and its salts t
BR112014020184B1 (en) PHARMACEUTICAL PREPARATION CONTAINING ANLODIPINE AND RA-MIPRIL
EP3331502B1 (en) Controlled release propiverine formulations
KR20210079216A (en) Pharmaceutical Formulation comprising Cibenzoline or a salt thereof
EP3796908B1 (en) Controlled release propiverine formulations
EP1663212A1 (en) Solid dosage formulation containing a factor xa inhibitor and method
US8512746B2 (en) Extended release pharmaceutical compositions of levetiracetam
JP4696210B2 (en) Sustained-release tablets containing isosorbide-5-mononitrate as an active ingredient and method for producing the same
JP2009525953A (en) Sustained release formulation of divalproic acid and its derivatives
AU2022410683A1 (en) A stable extended release pharmaceutical composition of clozapine
WO2024162929A1 (en) A controlled release formulation of propiverine
HK40072164A (en) Pharmaceutical formulation comprising cibenzoline or salt thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807614

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008807614

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE